Literature DB >> 23893074

Pain management in neurocritical care.

Axel Petzold1, Armand Girbes.   

Abstract

The core challenge of pain management in neurocritical care is to keep the patient comfortable without masking or overlooking any neurological deterioration. Clearly in patients with a neurological problem there is a conflict of clinical judgement and adequate pain relief. Here we review the presentation, assessment, and development of pain in the clinical spectrum of patients with associated neurological problems seen in a general intensive care setting. Many conditions predispose to the development of chronic pain. There is evidence that swift and targeted pain management may improve the outcome. Importantly pain management is multidisciplinary. The available non-invasive, pharmacological, and invasive treatment strategies are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23893074     DOI: 10.1007/s12028-013-9851-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  339 in total

1.  Gabapentin for treatment of thalamic pain syndrome.

Authors:  N Holtom
Journal:  Palliat Med       Date:  2000-03       Impact factor: 4.762

2.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

3.  Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Authors:  Alison M Haddow; Dawn Harris; Martin Wilson; Hannah Logie
Journal:  BMJ       Date:  2004-12-04

4.  Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2005-02-25       Impact factor: 47.728

5.  Anesthetic implications for video assisted thoracoscopic thymectomy in myasthenia gravis.

Authors:  Abdelazeem A El-Dawlatly; Khaled Al Kattan; Waseem Hajjar; Mohamed Essa; Bilal Delvi; Abdulaziz Khoja
Journal:  Middle East J Anaesthesiol       Date:  2005-06

6.  The sural sensory action potential in Guillain-Barré syndrome.

Authors:  N M Murray; D T Wade
Journal:  Muscle Nerve       Date:  1980 Sep-Oct       Impact factor: 3.217

7.  Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.

Authors:  N Hamaoka; Y Oda; I Hase; K Mizutani; T Nakamoto; T Ishizaki; A Asada
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

8.  Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.

Authors:  J Blum; S Nkunku; C Burri
Journal:  Trop Med Int Health       Date:  2001-05       Impact factor: 2.622

9.  Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial.

Authors:  Stephen Daniels; Timothy Melson; Douglas A Hamilton; Eric Lang; Daniel B Carr
Journal:  Clin J Pain       Date:  2013-08       Impact factor: 3.442

10.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Authors:  Gareth Pryce; Zubair Ahmed; Deborah J R Hankey; Samuel J Jackson; J Ludovic Croxford; Jennifer M Pocock; Catherine Ledent; Axel Petzold; Alan J Thompson; Gavin Giovannoni; M Louise Cuzner; David Baker
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.